var data={"title":"Budesonide (oral inhalation): Drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Budesonide (oral inhalation): Drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/771533?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=budesonide-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Budesonide (oral inhalation): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=budesonide-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Budesonide (oral inhalation): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663542\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pulmicort;</li>\n      <li>Pulmicort Flexhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663543\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pulmicort Turbuhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663546\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Inhalant (Oral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663591\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma: Inhalation</b>\n      <b>:</b> Titrate to lowest effective dose once patient is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmicort Flexhaler: Dry powder inhaler: Initial: 360 mcg twice daily (selected patients may be initiated at 180 mcg twice daily); maximum: 720 mcg twice daily; <b>Note:</b> May increase dose after 1 to 2 weeks of therapy in patients who are not adequately controlled</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmicort Turbuhaler [Canadian product]: Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial (or during periods of severe asthma or when switching from oral corticosteroid therapy): 400 to 2,400 mcg daily in 2 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 200 to 400 mcg twice daily (higher doses may be needed for some patients). Patients taking 400 mcg/day may take as a single daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Asthma guidelines:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program guidelines (NAEPP 2007): Dry powder inhaler (refers to the Pulmicort Flexhaler available in US). <b>Note:</b> Administer in divided doses twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ldquo;Low&rdquo; dose: 180 to 600 mcg/day</p>\n    <p style=\"text-indent:2em;margin-left:4em;\">&ldquo;Medium&rdquo; dose: &gt;600 to 1,200 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ldquo;High&rdquo; dose: &gt;1,200 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Global Initiative for Asthma guidelines (GINA 2016): Dry powder inhaler (refers to the Pulmicort Turbuhaler available in Canada):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ldquo;Low&rdquo; dose: 200 to 400 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ldquo;Medium&rdquo; dose: &gt;400 to 800 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ldquo;High&rdquo; dose: &gt;800 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Conversion:</i></b> <i>Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:</i> Initiation of inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 to 10 days after starting inhaled therapy. The manufacturer labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) on a weekly basis (patients using oral inhaler) or by &le;25% every 1 to 2 weeks (patients using respules). <b>Note:</b> When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic obstructive pulmonary disease (acute exacerbation) (off-label use):</b> Nebulization solution: 2 mg every 6 hours (Maltais 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic obstructive pulmonary disease (stable) (off-label use):</b> Inhalation: 100 to 400 mcg daily in combination with a long-acting bronchodilator (GOLD 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Eosinophilic esophagitis (off-label use):</b> Oral: 2 mg/day as an oral budesonide viscous liquid/suspension. Dose may be divided into 2 doses. Avoid ingesting any solid or liquid food for 30 minutes after budesonide administration. (Dellon 2013; Dohil 2010; Liacouras 2011; Rubinstein 2014). See Extemporaneously Prepared.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663590\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=budesonide-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Budesonide (oral inhalation): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Titrate to lowest effective dose once patient is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Inhalation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmicort Flexhaler: Dry powder inhaler: Children &ge;6 years of age: Initial: 180 mcg twice daily (some patients may be initiated at 360 mcg twice daily); maximum: 360 mcg twice daily; <b>Note:</b> May increase dose after 1 to 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmicort Turbuhaler [Canadian product]: Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial (or during periods of severe asthma or when switching from oral corticosteroid therapy): 200 to 400 mcg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Individualized, lowest effective dose in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years of age: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Asthma guidelines:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program guidelines (NAEPP 2007): Dry powder inhaler (refers to the Pulmicort Flexhaler available in US). <b>Note: </b>Administer in divided doses twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Low&rdquo; dose: 180 to 400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Medium&rdquo; dose: &gt;400 to 800 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;High&rdquo; dose: &gt;800 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Global Initiative for Asthma guidelines (GINA 2016): Dry powder inhaler (refers to the Pulmicort Turbuhaler available in Canada):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Low&rdquo; dose: 100 to 200 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Medium&rdquo; dose: &gt;200 to 400 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;High&rdquo; dose: &gt;400 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion:</b> <i>Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:</i> Initiation of inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 to 10 days after starting inhaled therapy. The manufacturer labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) on a weekly basis (patients using oral inhaler) or by &le;25% every 1 to 2 weeks (patients using respules). <b>Note:</b> When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Nebulization solution:</b> Pulmicort Respules: Children 12 months to 8 years: Titrate to lowest effective dose once patient is stable; start at 0.25 mg/day or use as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Previous therapy of bronchodilators alone: 0.5 mg/day administered as a single dose or divided twice daily (maximum daily dose: 0.5 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Previous therapy of inhaled corticosteroids: 0.5 mg/day administered as a single dose or divided twice daily (maximum daily dose: 1 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Previous therapy of oral corticosteroids: 1 mg/day administered as a single dose or divided twice daily (maximum daily dose: 1 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Asthma guidelines:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program guidelines (NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 0 to 4 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Low&rdquo; dose: 0.25 to 0.5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Medium&rdquo; dose: &gt;0.5 to 1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;High&rdquo; dose: &gt;1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Low&rdquo; dose: 0.5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Medium&rdquo; dose: 1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;High&rdquo; dose: 2 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Global Initiative for Asthma guidelines (GINA 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;5 years of age: &ldquo;Low&rdquo; dose: 0.5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Low&rdquo; dose: 0.25 to 0.5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;Medium&rdquo; dose: &gt;0.5 to 1 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;High&rdquo; dose: &gt;1 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral: Eosinophilic esophagitis (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &ge;10 years of age or &ge;5 ft in height:</i> 2 mg/day as an oral budesonide viscous liquid/suspension. Dose may be divided into 2 doses. Avoid ingesting any solid or liquid food for 30 minutes after budesonide administration. (Dellon 2013; Dohil 2010; Liacouras 2011; Rubinstein 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &lt;10 years of age or &lt;5 ft in height:</i> 1 mg/day as an oral budesonide viscous liquid/suspension. Avoid ingesting any solid or liquid food for 30 minutes after budesonide administration. (Dellon 2013; Dohil 2010; Liacouras 2011; Rubinstein 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> See Extemporaneously Prepared field.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663592\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663593\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663594\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, budesonide undergoes hepatic metabolism; drug may accumulate with hepatic impairment; use with caution; monitor closely for signs and symptoms of hypercortisolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663608\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pulmicort Flexhaler: 90 mcg/actuation (1 ea); 180 mcg/actuation (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pulmicort: 0.25 mg/2 mL (2 mL); 0.5 mg/2 mL (2 mL); 1 mg/2 mL (2 mL) [contains disodium edta, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg/2 mL (2 mL); 0.5 mg/2 mL (2 mL); 1 mg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663544\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663610\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pulmicort Flexhaler 180 mcg/actuation canisters contain 120 actuations and the 90 mcg/actuation canisters contain 60 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663611\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmicort Turbuhaler: 100 mcg/inhalation [delivers 200 metered actuations]; 200 mcg/inhalation [delivers 200 metered actuations]; 400 mcg/inhalation [delivers 200 metered actuations]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663596\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmicort Flexhaler: Hold inhaler in upright position (mouthpiece up) to load dose. Do not shake prior to use. Unit should be primed prior to first use only. It will not need primed again, even if not used for a long time. Place mouthpiece between lips and inhale forcefully and deeply. Do not exhale through inhaler; do not use a spacer. Dose indicator does not move with every dose, usually only after 5 doses. Discard when dose indicator reads &ldquo;0&rdquo;. Rinse mouth with water after each use to reduce incidence of candidiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmicort Turbuhaler [Canadian product]: Hold inhaler in upright position (mouthpiece up) to load dose. Do not shake inhaler after dose is loaded. Unit should be primed prior to first use. Place mouthpiece between lips and inhale forcefully and deeply; mouthpiece should face up. Do not exhale through inhaler; do not use a spacer. When a red mark appears in the dose indicator window, 20 doses are left. When the red mark reaches the bottom of the window, the inhaler should be discarded. Rinse mouth with water after use to reduce incidence of candidiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization solution: Shake well before using. Use Pulmicort Respules with jet nebulizer connected to an air compressor; administer with mouthpiece or facemask. Do not use ultrasonic nebulizer. Do not mix with other medications in nebulizer. Rinse mouth following treatments to decrease risk of oral candidiasis (wash face if using face mask).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663550\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization: Maintenance and prophylactic treatment of asthma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation: Maintenance and prophylactic treatment of asthma; includes patients who require oral corticosteroids and those who may benefit from systemic dose reduction/elimination</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Guideline recommendations: Asthma: A low-dose inhaled corticosteroid (<i>in addition to an as-needed short acting beta <sub>2</sub>-agonist</i>) is the initial preferred long term control medication for children, adolescents, and adult patients with persistent asthma who are candidates for treatment according to a step-wise treatment approach (GINA 2016; NAEPP 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663551\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic obstructive pulmonary disease (stable) (oral inhalation); Chronic obstructive pulmonary disease (acute exacerbation); Eosinophilic esophagitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663561\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\"> Frequencies are for both formulations unless otherwise indicated. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Otitis media (suspension: 12%; powder: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Respiratory infection (suspension: 38%; powder: &ge;3%), rhinitis (5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Syncope (powder: 1% to 3%), chest pain (suspension: 1% to &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (powder: &ge;3%; suspension: &lt;1%), pain (powder: &ge;3%), hypertonia (powder: 1% to 3%), insomnia (powder: 1% to 3%), voice disorder (powder: 1% to 3%), emotional lability (suspension: 1% to &lt;3%), fatigue (suspension: 1% to &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (suspension: 4%; powder: &lt;1%), contact dermatitis (suspension: 1% to &lt;3%), eczema (suspension: 1% to &lt;3%), pruritus (suspension: 1% to &lt;3%), pustular rash (suspension: 1% to &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Endocrine &amp; metabolic: Weight gain (1% to 3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (&ge;5%), nausea (2% to &ge;5%), gastroenteritis (suspension: 5%), diarrhea (suspension: 4%), vomiting (1% to 4%), abdominal pain (1% to 3%), dysgeusia (powder: 1% to 3%), xerostomia (powder: 1% to 3%), anorexia (suspension: 1% to &lt;3%), viral gastroenteritis (powder: 2%), oral candidiasis (powder: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Ecchymosis (powder: 1% to 3%), cervical lymphadenopathy (suspension: 1% to &lt;3%), purpura (suspension: 1% to &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (1% to &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Candidiasis (suspension: 4% to 5%), viral infection (suspension: 4% to 5%), infection (1% to 3%), herpes simplex infection (suspension: 1% to &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (&ge;5%), weakness (&ge;5%), back pain (powder: &ge;3%), bone fracture (1% to 3%), myalgia (1% to 3%), neck pain (powder: 1% to 3%), hyperkinesia (suspension: 1% to &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis (suspension: 4%), eye infection (suspension: 1% to &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Otic infection (suspension: 5%), otalgia (suspension: 1% to &lt;3%), otitis externa (suspension: 1% to &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Nasopharyngitis (powder: 9%), cough (5% to 9%), epistaxis (suspension: 2% to 4%), respiratory tract infection (powder: &ge;3%), sinusitis (powder: &ge;3%; suspension: &lt;1%), nasal congestion (powder: 3%), pharyngitis (powder: 3%; suspension: &lt;1%), flu-like symptoms (suspension: 1% to &lt;3%), stridor (suspension: 1% to &lt;3%), allergic rhinitis (powder: 2%), viral upper respiratory tract infection (powder: 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (&ge;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Adrenocortical insufficiency, aggressive behavior, anxiety, avascular necrosis of femoral head, bronchitis, bruise, cataract, depression, glaucoma, growth suppression, hypercorticoidism, increased intraocular pressure, irritability, nervousness, osteoporosis, pain, psychosis, restlessness, skin irritation (facial), throat irritation, wheezing </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663558\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to budesonide or any component of the formulation; severe hypersensitivity to milk proteins (Pulmicort Flexhaler); primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Moderate-to-severe bronchiectasis, pulmonary tuberculosis (active or quiescent), untreated respiratory infection (bacterial, fungal, or viral)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663559\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children, in patients receiving high doses for prolonged periods, or with concomitant CYP3A4 inhibitor use. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products or corticosteroids with lower systemic effect due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients directly from oral corticosteroid therapy. Select surgical patients on long-term, high-dose, inhaled corticosteroid (ICS), should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs stop steroid and treat with a fast-acting bronchodilator (eg, albuterol).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local oral infections: <i>Candida albicans</i> infections may occur in the mouth and pharynx; rinsing (and spitting) with water after inhaler use may decrease risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants or oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF or hypertension; long-term use has been associated with fluid retention and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention. Increased oral bioavailability has been reported in patients with cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarction: Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Pulmicort Flexhaler contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663568\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663565\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104949&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Budesonide (Oral Inhalation). Management: Concomitant use of these agents is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits. If combined, monitor patients closely for signs and symptoms of corticosteroid excess/toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663553\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (inhalation) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663554\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may also influence fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor. When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010). Budesonide may be used for the induction of remission in pregnant women with inflammatory bowel disease (Habal 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on available data, an overall increased risk of congenital malformations or a decrease in fetal growth has not been associated with maternal use of inhaled corticosteroids during pregnancy (Bakhireva 2005; NAEPP 2005; Namazy 2004). In addition, studies of pregnant women specifically using inhaled budesonide have not demonstrated an increased risk of congenital abnormalities. Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, pre-eclampsia, preterm birth, low birth weight infants). Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; budesonide is preferred (ACOG 2008; NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663557\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Following use of the powder for oral inhalation, ~0.3% to 1% of the maternal dose was found in breast milk. The maximum concentration appeared within 45 minutes of dosing. Plasma budesonide levels obtained from infants ~90 minutes after breast-feeding (~140 minutes after maternal dose) were below the limit of quantification. Concentrations of budesonide in breast milk are expected to be higher following administration of oral capsules/tablets than after an inhaled dose. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the manufacturer of the product for inhalation, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of minimal exposure to the infant and the benefits of breast-feeding to the mother. The use of inhaled corticosteroids is not considered a contraindication to breast-feeding (NAEPP 2005). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663599\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor growth in pediatric patients; blood pressure, serum glucose, weight with high-dose or long-term oral use; signs and symptoms of hypercortisolism or adrenal suppression; bone mineral density</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asthma: FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663574\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation. Has potent glucocorticoid activity and weak mineralocorticoid activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663576\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Nebulization: 2 to 8 days; Inhalation: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Nebulization: 4 to 6 weeks; Inhalation: 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 6 years: 3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 2.2 to 3.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 85% to 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4 to two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide; both are &lt;1% as active as parent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebulization: Children 4 to 6 years: 6%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral inhalation: 39% of an inhaled metered dose is available systemically</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 6 years: 2.3 hours (after nebulization)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 10 to 14 years: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 2 to 3.6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebulization: Pulmicort Respules: Children: 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral inhalation: Pulmicort Flexhaler: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents: 15 to 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60%) and feces as metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 4 to 6 years: 0.5 L/minute (~50% greater than healthy adults after weight adjustment) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 0.9 to 1.8 L/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28663613\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Pulmicort Flexhaler Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mcg/ACT (1): $205.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/ACT (1): $275.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Budesonide Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/2 mL (2 mL): $9.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/2 mL (2 mL): $11.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/2 mL (2 mL): $12.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Pulmicort Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/2 mL (2 mL): $10.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/2 mL (2 mL): $12.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/2 mL (2 mL): $24.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45649865\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aeronide (TH);</li>\n      <li>Aerovent (AR);</li>\n      <li>Aircort (MT);</li>\n      <li>B Cort (CO);</li>\n      <li>Benita (VN);</li>\n      <li>Budecort (MY, VN);</li>\n      <li>Budenocort (NZ);</li>\n      <li>Budeson (AR, BD);</li>\n      <li>Budiair Jet (BG);</li>\n      <li>Busonid (BR);</li>\n      <li>Denecort (PH);</li>\n      <li>Duasma HFA (HK);</li>\n      <li>Frenolyn (SG, TR);</li>\n      <li>Giona Easyhaler (SG, TH);</li>\n      <li>Inflammide (PE);</li>\n      <li>Miflonid (CZ);</li>\n      <li>Miflonide (AT, BE, CL, DE, DK, EC, EE, ES, IL, IT, NZ, PT, TR);</li>\n      <li>Neumocort (PY);</li>\n      <li>Novopulmon (DE, FR);</li>\n      <li>Numark (MX);</li>\n      <li>Pulmax (ZA);</li>\n      <li>Pulmicort (AE, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DK, EE, EG, FI, FR, GB, GR, HK, HU, ID, IE, IN, IS, JO, JP, KR, KW, LB, LU, LV, MX, NL, NO, NZ, PK, PL, PT, QA, RO, RU, SA, SE, SG, SK, TH, TR, TW, UA, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA; American College of Gastroenterology. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). <i>Am J Gastroenterol</i>. 2013 May;108(5):679-92; quiz 693.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/23567357/pubmed\" target=\"_blank\" id=\"23567357\">23567357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. <i>Gastroenterology</i>. 2010;139(2):418-429.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/20457157/pubmed\" target=\"_blank\" id=\"20457157\">20457157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2016. Accessed June 8, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Strategy for Diagnosis Management of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014. Available at: http://www.goldcopd.org.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM and Huang VW, &quot;Review Article: A Decision-Making Algorithm For the Management of Pregnancy in the Inflammatory Bowel Disease Patient,&quot; <i>Aliment Pharmacol Ther</i>, 2012, 35(5):501-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. <i>J Allergy Clin Immunol</i>. 2011;128(1):3-20.e6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/21477849/pubmed\" target=\"_blank\" id=\"21477849\">21477849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo; <i>Can Respir J</i>, 2010, 17(1):15-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/20186367/pubmed\" target=\"_blank\" id=\"20186367\">20186367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11874817\"></a>Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. <i>Am J Respir Crit Care Med</i>. 2002;165(5):698-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/11874817/pubmed\" target=\"_blank\" id=\"11874817\">11874817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2004, 113(3):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/15007341/pubmed\" target=\"_blank\" id=\"15007341\">15007341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed June 22, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulmicort Flexhaler (budesonide aerosol, powder) [prescribing information] S&ouml;dert&auml;lje, Sweden: AstraZeneca; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulmicort Respules (budesonide suspension) [prescribing information] S&ouml;dert&auml;lje, Sweden: AstraZeneca; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulmicort Turbuhaler (budesonide suspension) [prescribing information] Mississauga, Ontario, Canada: AstraZeneca; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubinstein E, Lee JJ, Fried A, et al. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children. <i>J Pediatr Gastroenterol Nutr</i>. 2014;59(3):317-320.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/24821535/pubmed\" target=\"_blank\" id=\"24821535\">24821535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd GR, Acerini CL, Buck JJ, et al, &quot;Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate,&quot; <i>Eur Respir J</i>, 2002, 19(6):1207-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/12108877/pubmed\" target=\"_blank\" id=\"12108877\">12108877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd GR, Acerini CL, Ross-Russell R, et al, &quot;Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom,&quot; <i>Arch Dis Child</i>, 2002, 87(6):457-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-oral-inhalation-drug-information/abstract-text/12456538/pubmed\" target=\"_blank\" id=\"12456538\">12456538</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104949 Version 52.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28663542\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28663543\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28663546\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28663591\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F28663590\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28663592\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28663593\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28663594\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28663608\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F28663544\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28663610\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F28663611\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28663596\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28663550\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28663551\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28663561\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28663558\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28663559\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28663568\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28663565\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28663553\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28663554\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28663557\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28663599\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28663574\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F28663576\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28663613\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45649865\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/104949|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=budesonide-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Budesonide (oral inhalation): Patient drug information \t</a></li><li><a href=\"topic.htm?path=budesonide-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">Budesonide (oral inhalation): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}